Vicuron Pharmaceuticals Announces 40 Presentations at ICAAC Highlighting Pipeline and Late-Stage Products

Vicuron Pharmaceuticals Announces 40 Presentations at ICAAC Highlighting Pipeline and Late-Stage Products KING OF PRUSSIA, Pa., Oct. 25 /PRNewswire-FirstCall/ -- Vicuron Pharmaceuticals Inc. (Nasdaq: MICU; Nuovo Mercato) today announced that researchers will present 40 presentations comprising clinical and preclinical data on the Company's pipeline of antibiotic and antifungal agents, including its two late-stage products, anidulafungin and dalbavancin, at the 44th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) meeting in Washington, D.C. this weekend. "Our traditionally strong scientific presence at ICAAC demonstrates our pipeline and commitment to and focus on an area of critical medical need," said George F. Horner III, President and Chief Executive Officer of Vicuron. "Key presentations will highlight the breadth of activity and potency of dalbavancin against Staphylococcus and anidulafungin against Candida biofilms. Ten presentations will highlight our lincomsamide program, from which we expect a new clinical candidate to emerge in the first half of next year. In addition, data from our collaborations with Novartis in peptide deformylase inhibitors and Pfizer in oxazolidinones also will be presented." Below are some of the highlights from this year's ICAAC meeting. Anidulafungin ORAL PRESENTATION: Anidulafungin Inhibits Candida albicans Biofilms In Vitro, Sunday, October 31, 3:15 PM, Experimental Mycology, M. K. Schinabeck, Case Western Reserve University/University Hospitals of Cleveland, M-1141. POSTER PRESENTATIONS: 1. Candida glabrata Resistance to Caspofungin During Therapy, Sunday, October 31, 1:30 PM, Clinical Mycology I, N.C. Villarreal, University of Texas Health Science Center at San Antonio, M-1034. 2. Efficacy of Anidulafungin (ANID) in Patients (Pts) with Azole- Refractory Mucosal Candidiasis (ARMC), Sunday, October 31, 1:30 PM, Clinical Mycology II, J. Vazquez, Wayne State University, M-1038. 3. Safety and Pharmacokinetics of Anidulafungin in Pediatric Patients with Neutropenia, Saturday, October 30, 10:00 AM, Pharmacokinetics of Antifungal Drugs, T. J. Walsh, National Cancer Institute, A-34/30. 4. Clinical Efficacy Results from a Phase 3 Study of Anidulafungin (ANID) versus Fluconazole (FLU) in HIV Negative Patients with Esophageal Candidiasis (EC), Sunday, October 31, 1:30 PM, Clinical Mycology I, J. Viljoen, Mediclinic Westdene, M-1023. Dalbavancin POSTER PRESENTATIONS: 1. Antibacterial Effect of Dalbavancin against MSSA, MRSA and VISA in an In Vitro Pharmacokinetic System, Sunday, October 31, 3:00 PM, In Vitro Pk/PD Models, K. E. Bowker, BCARE, A-1165/10. 2. Activity of Dalbavancin against Clinical Isolates of Staphylococci and Streptococci from the U.S. and Europe, Tuesday, Nov. 2, 10:00 AM, Cell Wall Inhibitors and Anti-Gram Positive Drugs, R. K. Flamm, Focus Technologies, E-2008/104. 3. Comparative Activity of Dalbavancin Tested against 7,771 Isolates from the U.S.A. and Europe (2003), Tuesday, Nov. 2, 10:00 AM, Cell Wall Inhibitors and Anti-Gram Positive Drugs, R. N. Jones, The JONES Group, E-2009/105 4. The Pharmacokinetics of Dalbavancin (DAL) in Subjects with Mild, Moderate or Severe Hepatic Impairment (HI), Saturday, October 30, 10:00 AM, Pharmacokinetics in Humans, J. A. Dowell, Vicuron Pharmaceuticals, A-19/15. Novel Lincosamides/VIC-5555 ORAL PRESENTATION: All New Antimicrobial Agents, VIC-105555: A Novel Lincosamide, Saturday, October 30, 10:00 AM, Oral presentation, Richard J. White, Ph.D. Vicuron Pharmaceuticals. POSTER PRESENTATIONS: 1. Novel Antimicrobial 7-Methyl Lincosamides: Prolamide Analogs, Monday, November 1, 10:00 AM, Novel Lincosamides/VIC-105555, J. G. Lewis, Vicuron Pharmaceuticals, F-1388/227. 2. Novel Antimicrobial 7-Methyl Lincosamides: Pipecolamide Analogs, Monday, November 1, 10:00 AM, Novel Lincosamides/VIC-105555, J. G. Lewis, Vicuron Pharmaceuticals, F-1389/228. 3. Inhibition of Protein Synthesis and Streptococcal Toxin Production by VIC-105555, Monday, November 1, 10:00 AM, Novel Lincosamides/VIC- 105555, P. S. Margolis, Vicuron Pharmaceuticals, F-1390/229. 4. Bactericidal Activity, Postantibiotic Effect and Frequency of Resistance of the Novel Lincosamide VIC-105555, Monday, November 1, 10:00 AM, Novel Lincosamides/VIC-105555, J. Blais, Vicuron Pharmaceuticals, F-1391/230. 5. VIC-105555, a New Lincosamide with Improved In Vivo Efficacy and Good In Vitro Activity, Monday, November 1, 10:00 AM, Novel Lincosamides/VIC-105555, C. Park, Vicuron Pharmaceuticals, F-1392/231. 6. Activity of VIC-105555 in Experimental Mouse Thigh and Pneumonia Infections, Monday, November 1, 10:00 AM, Novel Lincosamides/VIC- 105555, J. Blais, Vicuron Pharmaceuticals, F-1393/232. 7. Superior Efficacy of the New Lincosamide VIC-105555 Versus Clindamycin in Experimental S. aureus and B. fragilis Rat Pouch Infection, Monday, November 1, 10:00 AM, Novel Lincosamides/VIC-105555, D. Jabes, Vicuron Pharmaceuticals, F-1394/233. 8. Improved Pharmacokinetics of VIC-105555: Long Half-Life and Large Volume of Distribution in Multiple Species, Monday, November 1, 10:00 AM, Novel Lincosamides/VIC-105555, V. Tembe, Vicuron Pharmaceuticals, F-1395/234. 9. Extensive Tissue Distribution and Dose Response Pharmacokinetics of VIC-105555 in Rats, Monday, November 1, 10:00 AM, Novel Lincosamides/VIC-105555, V. Tembe, Vicuron Pharmaceuticals, F- 1396/235. Oxazolidinones and Peptide Deformylase Inhibitors POSTER PRESENTATIONS: 1. Thiadiazinone Phenyloxazolidinones with an Expanded Antibacterial Spectrum, Monday, November 1, 10:00 AM, Novel Oxazolidinones, G. W. Luehr, Vicuron Pharmaceuticals, F-1420/267. 2. LBM415, a New Peptide Deformylase Inhibitor with Potent In Vitro Activity against Drug-Resistant Bacteria, Tuesday, November 2, 8:30 AM, Peptide Deformylase Inhibitors/LBM415, N. S. Ryder, Novartis Institutes for BioMedical Research, Inc., F-1959/206. About Vicuron Vicuron Pharmaceuticals is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing vital medicine for seriously ill patients. In May 2004, Vicuron received an approvable letter from the FDA for its lead product anidulafungin for the treatment of esophageal candidiasis. The company's other lead product, dalbavancin, a novel intravenous antibiotic for the treatment of serious Gram-positive infections, has completed Phase 3 clinical trials. The Company's versatile research engine integrates industry-leading expertise in functional genomics, natural products discovery, mechanism-based drug design and combinatorial and medicinal chemistry. These approaches are yielding promising novel and next- generation compounds, many of which are in the later stages of preclinical development. In addition, the Company has research and development collaborations with leading pharmaceutical companies, such as Pfizer and Novartis. Forward-Looking Statements This news release contains forward-looking statements that predict or describe future events or trends. The matters described in these forward- looking statements are subject to known and unknown risks, uncertainties and other unpredictable factors, many of which are beyond Vicuron's control. Vicuron faces many risks that could cause its actual performance to differ materially from the results predicted by its forward-looking statements, including the possibilities that clinical trials and the results thereof might be delayed, or unsuccessful, that the timing of the filing of any new drug application or any amendment to a new drug application might be delayed, that clinical trials might indicate that a product candidate is unsafe or ineffective, that the FDA might require additional information to be submitted and additional actions to be taken before it will make any decision, that any filed new drug application may not be approved by the FDA, that ongoing proprietary and collaborative research might not occur or yield useful results, that the pipeline may not yield a new clinical candidate or a commercial product, that a third party may not be willing to license our product candidates on terms acceptable to us or at all, that competitors might develop superior substitutes for Vicuron's products or market these competitive products more effectively, that a sales force may not be developed as contemplated and that one or more of Vicuron's product candidates may not be commercialized successfully. The reports that Vicuron files with the U.S. Securities and Exchange Commission contain a fuller description of these and many other risks to which Vicuron is subject. Because of those risks, Vicuron's actual results, performance or achievements may differ materially from the results, performance or achievements contemplated by its forward- looking statement. The information set forth in this news release represents management's current expectations and intentions. Vicuron assumes no responsibility to issue updates to the forward-looking matters discussed in this news release. DATASOURCE: Vicuron Pharmaceuticals Inc. CONTACT: Dov A. Goldstein, M.D. of Vicuron Pharmaceuticals Inc., +1-610-205-2312, ; or Hala Mirza of WeissComm Partners, +1-212-204-2080, ; or Aline Schimmel of Burns McClellan Inc., +1-212-213-0006, , both for Vicuron Pharmaceuticals Inc. Web site: http://www.vicuron.com/